IPSEN (OTCMKTS:IPSEY) Sees Significant Decline in Short Interest

IPSEN (OTCMKTS:IPSEY) saw a significant drop in short interest in April. As of April 30th, there was short interest totaling 297 shares, a drop of 39.6% from the April 15th total of 492 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 680 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a report on Thursday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

IPSEN Price Performance

IPSEY stock traded down $0.10 during midday trading on Friday, reaching $48.76. The company’s stock had a trading volume of 109 shares, compared to its average volume of 870. IPSEN has a 52 week low of $28.59 and a 52 week high of $51.10. The business’s 50-day simple moving average is $47.22 and its 200-day simple moving average is $41.56.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).